Thymosin β4 significantly reduces the signs of dryness in a murine controlled adverse environment model of experimental dry eye

Abstract

Listen

Translate article

Objective: Dry eye syndrome is a common condition that affects up to 20% of the population aged 45 and older. There are no successful treatments to date. The goal of this research was to determine the efficacy of various doses and the optimal frequency of thymosin β4 (Tβ4) treatment in a murine severe dry eye model.Research design and methods: The study was performed using a controlled adverse environment chamber (CAE) in combination with scopolamine to induce moderate to severe dry eye in mice. The study included five mice per group and tested six different doses of Tβ4 twice per day for 12 days. Tβ4 at 0.1% was also administered 2 – 4 times per day for 12 days. Healing was measured by fluorescein staining.Main outcome measures: Tβ4 significantly reduced the signs of dry eye relative to controls. The treatment effect was more pronounced than the positive controls, doxycycline and Restasis (cyclosporine 0.05%). Active doses of 0.1 and 0.5% were determined, and it was found that the frequency of dosing at 2 times per day was the most effective for healing.Conclusions: Tβ4 has the potential to be an important new effective therapeutic for dry eye.